Focal degeneration of aged or injured myoepithelial cells and the resultant auto-immunoreactions are trigger factors for breast tumor invasion

Medical Hypotheses

Volumn 69, Issue 6, 2007, Pages 1340-1357

  Man, Yan gao ^a,b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GROWTH FACTOR; OXYGEN; TENASCIN;

ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER INVASION; CANCER RISK; CELL DEGENERATION; CELL INFILTRATION; CELL INVASION; CELL PROLIFERATION; DEGENERATION; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; HUMAN; IMMUNOREACTIVITY; INHIBITION KINETICS; MEMBRANE PERMEABILITY; MYOEPITHELIUM CELL; NUTRIENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; STROMA CELL; TUMOR GROWTH; VALIDITY;

AUTOIMMUNITY; BREAST NEOPLASMS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MATRIX METALLOPROTEINASES, SECRETED; NEOPLASM INVASIVENESS; OXYGEN; STEM CELLS; STROMAL CELLS;

ANIMALIA;

EID: 35448987018     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.02.031     Document Type: Article

References (143)

1. Tsubura A., Shikata N., Inui T., et al. Immunohistochemical localization of myoepithelial cells and basement membrane in normal, benign and malignant human breast lesions. Virch Arch A Pathol Anat Histopathol 413 (1988) 133-139
2. Gottlieb C., Raiu U., and Greenwald K.A. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study. Mod Pathol 3 (1990) 135-140
3. Jolicoeur F., Seemayer T.A., and Gabbiani G. Multifocal, nascent, and invasive myoepithelial carcinoma (malignant myoepithelioma) of the breast: an immunohistochemical and ultrastructural study. Int J Surg Pathol 10 (2002) 281-301
4. Guelstein V.I., Tehypysheva T.A., Ermilova V.D., and Liubimov A.V. Myoepithelial and basement membrane antigens in benign and malignant human breast tumors. In J Cancer 53 (1993) 269-277
5. Nerlich A. Morphology of basement membrane and associated matrix proteins in normal and pathological tissues. Veroff Pathol 145 (1995) 1-139
6. Bissell M.J., and Bilder D. Polarity determination in breast tissue: desmosomal adhesion, myoepithelial cells, and laminin 1. Breast Cancer Res 5 (2003) 117-119
7. Beckmann M.W., Niederacher D., Schnurch H.G., et al. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 75 (1997) 429-439
8. Schmitt F.C. Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer 31A (1995) 2049-2052
9. Clarke R., Brunner N., and Katzenellenbogen B.S. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86 (1989) 3649-3653
10. Goldfarb R.H., and Liotta L.A. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 12 (1986) 294-307
11. Duffy M.J., Maguire T.M., Hill A., et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2 (2000) 252-257
12. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 19 (1999) 1589-1592
13. Jones J.L., and Glymp Walker R.A. Expression of MMP-1 and MMP-9, their inhibitors, and activator MT1-MMP in primary breast carcinomas. J Pathol 189 (1999) 161-168
14. Cancer Trends Progress Report - 2005 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, December 2005. http://progressreport.cancer.gov.
15. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science 295 5564 (2002) 2387-2392
16. Matrisian L.M., Sledge Jr. G.W., and Mohla S. Exacellular proteolysis and cancer: meeting summary and future directions. Cancer Res 63 (2003) 6105-6109
17. Zhao Y.G., Xiao A.Z., Park H.I., et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinase-2 and 4: a putative role in the initiation of breast cancer invasion. Cancer Res 64 (2004) 590-598
18. Man Y.G., Shen T., Weisz J., et al. A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect Prev 29 (2005) 323-331
19. Man YG, Berg PE, Sang QXA. Differential expression of tumor invasion related proteins in cells overlying focally disrupted myoepithelial cell layers and adjacent cells within the same duct. In: Proceedings of Department of Defense breast cancer research program meeting, vol. 75; 2005. p. 10-5.
20. Man YG.A subset of cell clusters overlying focal myoepithelial cell layer disruptions exhibits features of mutated stem cells. In: Proceedings of Department of Defense breast cancer research program meeting, vol. P38; 2005. p. 263.
21. Sakorafas G.H., and Farley D.R. Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 12 (2003) 221-240
22. Baxter N.N., Virnig B.A., Durham S.B., and Tuttle T.M. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96 (2004) 443-448
23. Barillot I., Cutuli B., and Arnould L. Ductal in situ carcinoma: is it ethical to consider the breast conserving therapy as a standard?. Cancer Radiother 8 (2004) 9-20
24. Winchester D.J., Menck H.R., and Winchester D.P. National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 132 (1997) 660-665
25. Hwang E.S., and Esserman L.J. Management of ductal carcinoma in situ. Surg Clin North Am 79 (1999) 1007-1030
26. Dean L., and Geschickter C.F. Comedo carcinoma of the breast. Arch Surg 36 (1938) 225-234
27. Kraus F.T., and Neubecker R.D. The differential diagnosis of papillary tumors of the breast. Cancer 15 (1962) 444-455
28. Farrow J.H. Current concepts in the detection and treatment of the earliest of the earliest breast cancer 25 (1970) 468-477
29. Haagensen C.D., Lane N., and Lattes R. Neoplastic proliferation of the epithelium of the mammary lobules: adenosis, lobular hyperplasia, and small cell carcinoma. Surg Clin North Am 52 (1972) 497-524
30. Millis R.R., and Thynne G.S. In situ intraduct carcinoma of the breast: a long term follow-up study. Br J Surg 62 (1975) 957-962
31. Rosen P.P., Braun Jr. D.W., and Kinne D.E. The clinical significance of pre-invasive breast carcinoma. Cancer 46 (1980) 915-925
32. Page D.L., Duppont W.D., Rogers L.W., and Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 49 (1982) 751-758
33. Page D.L., Dupont W.D., Rogers L.W., Jensen R.A., and Schuyler P.A. Continues local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76 (1995) 1197-2000
34. Eusebi V., Feudale E., Foschini M.P., et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 11 (1994) 223-235
35. Rosen P.P. Rosen's breast pathology (2001), Lippncott Williams & Wilkins, Philadelphia, PA p. 257-323
36. Tavassoli F.A. Pathology of breast (1992), Elsevier, New York
37. Kasahara Y., and Tsukada Y. New insights and future advances in cancer diagnostics: limitations of conventional tumor markers. In: Nakarnura R.M., Grody W.W., Wu J.T., and Nagle R.B. (Eds). Cancer diagnostics: current and future trends (2004), Totowa, NJ, Humanna Press
38. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1988) 1542-1547
39. Warnberg F., Nordgren H., Bergkvist L., and Hulmberg L. Tumor markers in breast carcinomas correlate with grade rather than with invasiveness. Br J Cancer 85 (2001) 869-874
40. Farabegoli F., Champeme M.H., Bieche I., Santini D., Ceccareli C., Derenzini M., et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 196 (2002) 280-286
41. Parker S.L., Tong T., Bolders S., and Wingo P.A. Cancer statistics. Cancer J Clin 47 (1997) 5-27
42. Leonard G.D., and Swain S.M. Ductal carcinoma in situ, complexities and challenges. J Nat Cancer Inst 96 (2004) 906-920
43. Zaugg K., and Bodis S. Is there role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast?. Radiother Oncol 55 (2000) 95-99
44. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
45. Sheng S., Pemberton P.A., and Sager R. Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 269 (1994) 30988-30993
46. Barbareschi M., Pecciarini L., Cangi M.G., et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25 (2001) 1954-1960
47. Sternlight M.D., and Barsky S.H. The myoepithelial defense: a host defense against cancer. Med Hypotheses 48 (1997) 37-46
48. Man YG, Vang RS, Saenger JS, et al. Co-expression of maspin and wilms' tumor 1 proteins in mammary myoepithelial cells-implication for tumor progression and invasion. In: Proceedings of Department of Defense breast cancer research program meeting, vol. 1; 2002. p. 16.
49. Man Y.G., Tai L., Barner R., Vang R., et al. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res 5 (2003) R231-R241
50. Man YG, Tai L, Barner Ross, et al. Focal losses of ER expression in epithelial cells and disruptions of subjacent. myoepithelial cell layers are correlated events in ER (+) ductal intraepithelial neoplasia. Proceedings of Department of Defense breast cancer research program meeting, vol, 1; 2002. p. 17.
51. Man Y.G., Shekitka K.M., Bratthauer G.L., and Tavassoli F.A. Immunohistochemical and genetic alterations in mammary epithelial cells overlying focally disrupted myoepithelial cell layers. Breast Cancer Res Treat 76 sup 1 (2002) S143 S569
52. Man Y.G., Zeng X., Shen T., et al. Cell clusters overlying focally disrupted myoepithelial cell layers and their adjacent counterparts within the same duct display a different pattern of mRNA expression. Mod Pathol 17 supplement 1 (2004) 40a-41a
53. Man Y.G., Zhang Y., Shen T., et al. cDNA expression profiling identifies elevated expressions of tumor progression and invasion related genes in cell clusters of in situ breast tumors. Breast Cancer Res Treat 89 (2005) 199-208
54. Man Y.G., Zhao C.Q., and Wang J. Breast tumor cell clusters and their budding derivatives show different immunohistochemical profiles during stromal invasion: implications for hormonal and drug therapies. Cancer Ther 4 (2006) 193-204
55. Yousefi M., Mattu R., Gao C., and Man Y.G. Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: Implications for tumor progression and invasion. Appl Immunohistochem Mol Morphol 13 (2005) 30-37
56. Man YG. CD8 and mast cell tryptase positive cells are preferentially associated with focal myoepithelial cell layer disruptions: implications for breast tumor invasion. Proceedings of Department of Defense breast cancer research program meeting, vol. P38; 2005. p. 263.
57. Man YG. Focal degenerations in surrounding structures and infiltration of immunoreactive cells are a potential trigger for invasion of breast and other epithelium-derived tumors. Proceedings of Department of Defense breast cancer research program meeting, vol. P10; 2005. p. 75-6.
58. Man YG. CD8 and mast cell tryptase positive cells are differentially distributed in benign and malignant breast tissues with and without myoepithelial cell layers. Proceedings of Department of Defense breast cancer research program meeting, vol. P10-9; 2005; p. 76.
59. Man YG. Focal degeneration of aged or injured myoepithelial cells and resultant auto-immunoreactions trigger genomic instability and breast tumor invasion. In: Columbus F (Ed). New research on genomic instability. Nova Science Publishers, Inc, in press.
60. Verstraeten A.A., Mackie E.J., Hageman P.C., et al. Tenascin expression in basal cell carcinoma. Brit J Dermt 127 (1992) 571-574
61. Ilunga K., Nishiura R., Inada H., El-karef A., Imanaka-Yoshida K., Sakakura T., et al. Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenasicin-c enhances matrix metalloproteinase-9 expression and cancer cell invasion. Int J Exp Pathol 85 (2004) 373-379
62. Man YG, Saenger JS, Strauss B, et al. Focal alterations of p27 expression and subjacent myoepithelial cell layer disruptions are correlated events in ER(-) ductal intraepithelial neoplasia. Proceedings of Department of Defense breast cancer research program meeting, vol. 1; 2002. p. 9, 14.
63. Man Y.G., Vang R.S., Saenger J.S., et al. Development and progression of mammary ductal tumors appear to be mediated by surrounding myoepithelial cells. Mod Pathol 16 1 (2003) 39A-40A
64. Zhang R., Man Y.G., Strauss B.L., Vang R.S., Saenger J.S., Barner R., et al. A subset of morphologically identifiable mammary myoepithelial cells lacks expression of corresponding phenotypic markers. Mod Pathol 16 1 (2003) 52A
65. Man Y.G., Barner R., Vang R., et al. Non-smooth muscle restricted proteins exclusively or preferentially expressed in mammary myoepithelial cells: a programmed or induced phenomenon?. Mod Pathol 17 supplement 1 (2004) 40a
66. Wang L.P., Mannion C., and Man Y.G. Reduction of tumor suppressors and elevation of cytotoxic cells in myoepithelial cell layers of inflammation breast carcinoma: implication for tumor aggressiveness. Mod Pathol 18 (2005) 54A 238
67. Man Y.G., Wang J., and Cavalli L. Reduced p63 and elevated apoptosis in focally disrupted myoepithelial cell layers: early signs of breast tumor invasion?. Breast Dis 25 (2006) 13
68. Man YG, Shen T, Zhao YG, Sang QX. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: Implications for basal call layer degradation and tumor invasion. In: Cancer detection & prevention, 2004 symposium issue, vol. S-51; 2004. p. 15.
69. Man Y.G., Shen T., Zhao Y.G., and Sang Q.X. Morphologically comparable prostate acini and ducts with and without a focal basal cell layer disruption have a different cell proliferation rate: Implications for tumor invasion. FASEB 18 5 (2004) A1193
70. Man Y.G., Mannion C., and Shen T. Localized basal cell degeneration and resultant immunoreactions are a triggering factor for prostate tumor invasion. FASEB 19 (2005) A1517-A1518 860
71. Sang Q.X.A., Zhao Y.G., and Man Y.G. Mechanism of human prostate cancer invasion: basement membrane degradation and basal cell layer disruption. Proc Am Assoc for Cancer Res 46 (2005) 1106
72. Zhao C.Q., and Man Y.G. A subset of morphologically distinct prostate basal cells lacks expression of corresponding phenotypic markers. Am J Clin Pathol 124 4 (2005) 658-659
73. Wang H.L., and Man Y.G. Potential roles of focal basement membrane disruptions and lymphocyte infiltration in colorectal cancer invasion. Am J Clin Pathol 124 4 (2005) 647
74. Nelson A, Man YG. Mast cells in high grade lesions of patients co-infected with human papilloma virus and human immunodeficiency virus. Accepted for poster presentation at the 2006 USCAP Annual Meeting. Lab Investigation 2006; 86:257A, 1190.
75. Man YG, Chen XL, Garcia FU, Gardner WA. Reduced p63 expression and elevated apoptosis in focally disrupted prostate basal cell layers: implications for tumor invasion. Accepted for platform presentation at the 2006 USCAP Meeting. Lab Investigation 2006; 86:292A, 1358.
76. Man Y.G., Shen T., Zhao Y.G., and Sang Q.X. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect Prev 29 (2005) 161-169
77. Brummer T., Schramek D., Hayes V.M., Bennett H.L., Callon C.E., Musgrove E.A., et al. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 281 (2006) 626-631
78. Oliveira A.M., Ross J.S., and Fletcher J.A. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124 Suppl (2005) S16-S28
79. Yanochko G.M., and Eckhart W. Type 1 insulin-like growth factor overexpression induce proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res 8 2 (2006) R18
80. Boulikas T. Control of DNA replication by protein phosphorylation. Anticancer Res 14 (1994) 2465-2472
81. Boulikas T. Phosphorylation of transcription factors and control of the cell cycle. Crit Rev Eukaryot Gene Expr 5 (1995) 1-77
82. Chakravarthy M.V., Spangenhurg E.E., and Booth F.W. Culture in low levels of oxygen enhances in vitro proliferation potential of satellite cells from old skeletal muscles. Cell Mol Life Sci 58 (2001) 1150-1158
83. Csete M., Walikonis J., Slawny N., et al. Oxygen-mediated regulation of skeletal muscle satellite cell proliferation and adipogenesis in culture. J Cell Physio 189 (2001) 189-196
84. Studer L., Csete M., and Lee S.H. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowed pxygen. J Neurosci 20 (2000) 7377-7383
85. Asano-kato N., Fukagawa K., and Okada N. Tryptase increase proliferative activity of human conjunctive fibroblasts through protease-activated receptor. Invest Ophthalmol Vis Sci 46 (2005) 4622-4626
86. Freeman M.R., Schneck F.X., Gognon M.L., Corless C., Soker S., Niknejad K., et al. Peripheral blood T-lymphocytes and lymphocytes infiltrating human cancers express vascular endothelianl growth factor: a potential role for T cells in angiogenesis. Cancer Res 55 (1995) 4140-4145
87. Nienartowicz A., Sobaniee-Lotowska M.E., et al. Mast cells in neoangiogenesis. Med Sci Monit 12 3 (2006) RA 53-RA 56
88. Qu Z. Immunohistological detection of growth factors and cytokines in tissue mast cells. Meth Mol Biol 315 (2006) 257-272
89. Takahashi Y., Bucana C.D., Liu W., Yoneda J., Kitadai Y., Cleary K.R., et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88 (1996) 1146-1151
90. Kang Y., and Massague J. Epithelial-mesenchymal transition: twist in development and metastasis. Cell 118 (2004) 277-279
91. Sato T., Sakai T., Noguchi Y., Takita M., Hirakawa S., and Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92 (2004) 47-56
92. Strizzi L., Bianco C., and Normanno N. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Criptol-1 transgenic mice. J Cell Physiol 201 (2004) 266-276
93. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 4260 (1976) 23-28
94. Sell S., and Pierce G.B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 70 (1994) 6-22
95. Kordon E.C., and Smith G.H. An entire functional mammary gland may comprise the progeny from a single cell. Development 125 (1998) 1921-1930
96. Middleton L.P., Vlastos G., Mirza N.Q., Eva S., and Sahin A.A. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer 94 (2000) 1910-1916
97. Bjerkvig R., Tysnes B.B., Aboody K.S., et al. Opinion: the origin of the cancer stem cell: current controversies and new insight. Nat Rev Cancer 5 (2005) 899-904
98. Man Y.G., and Nieburgs H.E. A subset of morphologically normal and hyperplastic breast tissues contains cell clusters with malignant features: implication for tumor progression and invasion. Cancer Detect Prev 30 (2006) 239-247
99. Deng G., Liu Y., Ziotnikov G., et al. Loss of heterogosity in normal tissue adjacent to breast carcinomas. Science 274 5295 (1996) 2057-2059
100. Malins D.C., Polissar N.L., Su Y., Gardner H.S., and Gunselman S.J. A new structural analysis of DNA using statistical models of infrared sepctra. Nat Med 3 (1997) 927-930
101. Malins D.C., Johnson P.M., Barker E.A., Polissar N.L., Wheeler T.M., and Anderson K.M. Cancer-related changes in prostate DNA as men age and early identification of metastasis in pristate tumors. Proc Natl Acad Sci USA 100 (2003) 5401-5406
102. Malins D.C., Anderson K.M., Gilman N.K., Green V.M., Barker E.A., and Hellstrom K.E. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci Sci USA 101 (2004) 10721-10725
103. Malins D.C., Gilman N.K., Green V.M., Wheeler T.M., Barker E.A., and Anderson K.M. A DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA 102 (2005) 19093-19096
104. Benoist C., and Mathis D. Mast cells in autoimmune disease. Nature 420 (2002) 875-878
105. Palapattu G.S., Sutcliffe S., Bastian P.J., Platz E.A., De Marzo A.M., Isaacs W.B., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26 (2005) 1170-1181
106. Steadman R., Irwin M.H., St John P.L., Blackburn W.D., Heck L.W., and Abrahamson D.R. Laminin cleavage by activated human neutrophils yields proteolytic fragments with selective migratory properties. J Leukoc Biol 53 (1993) 354-365
107. Heck L.W., Blackburn W.D., Irwin M.H., and Abrahamson D.R. Degradation of basement membrane laminin by human neutrophil elastases and cathepsin G. Am J Pathol 136 (1990) 1267-1274
108. Peek Jr. R.M., Mohla S., and DuBois R.N. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res 65 (2005) 8583-8586
109. MacLennan G.T., Eisenberg R., Fleshman R.L., et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year follow-up study. J Urol 176 (2006) 1012-1016
110. Fibach E., Landau T., and Sachs L. Normal differentiation of myeloid leukaemic cells induced by a differentiation-inducing protein. Nat New Biol 237 (1972) 276-282
111. Nakamura T., Matsumoto K., Kiritoshi A., Tano Y., and Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor- stromal interactions. Cancer Res 57 (1997) 3305-3313
112. Silberstein G.B. Tumour-stromal interactions. Role of the stroma in mammary development. Breast Cancer Res 3 (2001) 218-223
113. Man Y.G., Magrane G.G., Lininger R.A., Shen T., Kuhls E., and Bratthauer B.L. Morphologically similar epithelial and stromal cells in primary bilateral breast tumors display different genetic profiles: implications for treatment. Appl Immunohistochem Mol Morphol 12 (2004) 305-314
114. Moinfar F., Man Y.G., Arnould L., Bratthauer G.L., Ratschek M., and Tavassol F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60 (2000) 2562-2566
115. Man Y.G., Martinez A., Avis I.M., Hong S.H., Cuttitta F., Venzon D.J., et al. Am J Respir Cell Mol Biol 23 (2000) 636-645
116. Man Y.G., Mannion C., Albores-Saaverdra J., et al. Allelic losses at 3p and 11p are detected in both epithelial and stromal components of cervical small cell neuroendocrine carcinoma. Appl Immunohistochem Mol Morphol 9 (2001) 340-345
117. Moinfar F., Gogg-Kamerer M., Sommersacher A., et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am J SurgPathol 29 (2005) 485-489
118. De Maria R., Olivero M., Iussich S., et al. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 65 (2005) 907-912
119. Kuperwasser C., Hurlbut G.D., Kittrell F.S., et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 157 (2000) 2151-2159
120. Pazos P., Lanari C., Meiss R., et al. Mammary carcinogenesis induced by N-methyl-N-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) in BALB/c mice. Breast Cancer Res Treat 20 (1992) 133-138
121. Williams J.C., Gusterson B., Humphreys J., et al. N-Methyl-N-nitrosourea-induced rate mammary tumors. Hormone responsiveness but lack of spontaneous metastasis. J Natl Cancer Inst 66 (1981) 147-155
122. Thompson H.J., McGinley J.N., Wolfe P., et al. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis 19 (1998) 2181-2185
123. Clarke R., Brunner N., and Katzenellenbogen B.S. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86 (1989) 3649-3653
124. Schmitt F.C. Multistep progression from an estrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur J Cancer 31A (1995) 2049-2052
125. Sheikh M.S., Garcia M., Pujol P., et al. Why are estrogen receptor negative breast cancers more aggressive than the estrogen receptor positive breast cancers?. Invas Metast 14 (1994-1995) 329-336
126. Rochefort H., Glondu M., Sahla M.E., Platat N., and Garcia M. How to target estrogen receptor-negative breast cancer. Endocr Relat Cancer 10 (2003) 261-266
127. Jourquin J., Yang N., Kam Y., Geuss C., and Quaranta V. Dispersal of epithelial cancer cell colonies by lysophosphatidic acid (LPA). J Cell Physiol 206 (2006) 337-346
128. Mailleux A.A., Spencer-Dene B., Dillon C., et al. Role of FGF10/GFR2b signaling during mammary gland development in the mouse embryo. Development 129 (2002) 53-60
129. Metzger R.J., and Krasnow M.A. Genetic control of branching morphogenesis. Science 284 5420 (1999) 1635-1639
130. Lu J., Izyolsky K.I., and Qian J. Identification of FGF10 targets in the embryonic lung epithelium during bud morphogenesis. J Biol Chem 280 (2005) 4834-4841
131. Yang M., Moriya T., DeLa Cruz C., et al. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int 53 (2003) 422-428
132. Korpsmeier K.H. Proliferation kinetics in the mammary gland of the mouse during postnatal development. Anat Anz 145 (1979) 313-318
133. Gudjonsson T., Adriance M.C., Sternlicht M.D., et al. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 10 (2005) 261-272
134. Adriance M.C., Inman J.L., Petersen O.W., and Bissell M.J. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res 7 (2005) 190-197
135. Sapino A., Macri L., Tonda L., and Bussolati G. Oxytocin enhance myoepithelial cell differentiation and proliferation in mouse mammary mammary gland. Endocrinology 133 (1993) 838-842
136. Tobacman J.K. Filament disassembly and loss of mammary myoepithelial cells after exposure to lambda-carrageenan. Cancer Res 57 (1997) 2823-2826
137. Tobacman J.K., and Walters K.S. Carrageenan-induced inclusion in mammary myoepithelial cells. Cancer Detec Prev 25 (2001) 520-526
138. Foschini M.P., and Eusebi V. Carcinoma of the breast showing myoepithelial cell differentiation. A review of the literature. Virchows Arch 432 (1998) 308-310
139. Coyne J.D., Dervan P.A., and Barr I. High-grade carcinoma of the breast showing patterns of mixed ductal and myoepithelial differentiation (including myoepithelial cell-rich carcinoma of the breast). Histopathology 44 (2004) 580-584
140. Tavassoli F.A. Myoepithelial lesions of the breast: myoepitheliosis, adenomyoepithelioma, and myoepithelial carcinoma. Am J Surg Pathol 15 (1991) 554-568
141. Thorner P.S., Kahn H.J., Baumal R., et al. Malignant myoepithelioma of the breast: an immunohistochemical study by light and electron microscope. Cancer 57 (1986) 745-750
142. Zhang R., Man Y.G., Vang R.S., et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res 5 (2003) R151-R156
143. Man Y.G., Zhao C.Q., Wang J., and XL C. A subset of prostate basal cells lacks corresponding phenotypic markers. Pathol Res Pract 202 9 (2006) 651-662